title: Islet cell carcinoma of the pancreas.
abstract: Islet cell carcinoma (ICC) of the pancreas is a rare, indolent malignancy associated with higher resectability rate and better survival than ductal carcinoma. This retrospective study presents results of surgical treatment from a single institution. From 1985 through 1993 a total of 64 patients (36 men, 28 women) were surgically treated for ICC. Ages ranged from 22 to 80 years (median 55 years) with a median postoperative follow-up of 39 months (range 10-97 months). Of the 64 patients, 30 (47%) had functioning and 34 (53%) nonfunctioning tumors. Gastrinoma (n = 11) followed by glucagonoma (n = 6) and insulinoma (n = 4) were the most common functioning tumors. In the patients undergoing a laboratory study, 67% of the nonfunctioning tumors had elevated peptide hormone levels. Potentially curative resections were performed in 17 patients (26%), palliative procedures in 35 (55%), and exploratory laparotomy alone in 12 (19%). One patient (2%) died within 30 days after operation. Symptomatic improvement was achieved in 96% of patients with a mean duration of 22 months. Three- and five-year survivals were 66% and 49%, respectively. In patients with curative resection, the disease-free survival at 3 years was 53% (95% CI: 32-86%). The presence of diffuse hepatic metastases was a predictor of poor survival at 3 years (74% versus 58%;p = 0.05); there was no statistically significant difference in survival between functioning and nonfunctioning groups (p > 0.1). Although curative resection for ICC is rare, meaningful palliation can be achieved in most patients with rare mortality and acceptable morbidity.
authors.affiliation: Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA.
authors.forename: C Y
authors.initials: CY
authors.lastname: Lo
authors.forename: J A
authors.initials: JA
authors.lastname: van Heerden
authors.forename: G B
authors.initials: GB
authors.lastname: Thompson
authors.forename: C S
authors.initials: CS
authors.lastname: Grant
authors.forename: J A
authors.initials: JA
authors.lastname: Söreide
authors.forename: W S
authors.initials: WS
authors.lastname: Harmsen
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018273:Carcinoma, Islet Cell / Q000556:secondary / Q000601:surgery*; D002423:Cause of Death; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D005544:Forecasting; D015408:Gastrinoma / Q000601:surgery; D005935:Glucagonoma / Q000601:surgery; D006801:Humans; D007340:Insulinoma / Q000601:surgery; D007813:Laparotomy; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D010190:Pancreatic Neoplasms / Q000601:surgery*; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome